TY - JOUR
T1 - Incidence and risk factors of intraocular inflammation after brolucizumab treatment in Japan
T2 - A Multicenter Age-Related Macular Degeneration Study
AU - Inoda, Satoru
AU - Takahashi, Hidenori
AU - Maruyama-Inoue, Maiko
AU - Ikeda, Shoko
AU - Sekiryu, Tetsuju
AU - Itagaki, Kanako
AU - Matsumoto, Hidetaka
AU - Mukai, Ryo
AU - Nagai, Yoshimi
AU - Ohnaka, Masayuki
AU - Kusuhara, Sentaro
AU - Miki, Akiko
AU - Okada, Annabelle A.
AU - Nakayama, Makiko
AU - Nishiguchi, Koji M.
AU - Takeuchi, Jun
AU - Mori, Ryusaburo
AU - Tanaka, Koji
AU - Honda, Shigeru
AU - Kohno, Takeya
AU - Koizumi, Hideki
AU - Miyara, Yasunori
AU - Inoue, Yuji
AU - Takana, Hiroki
AU - Iida, Tomohiro
AU - Maruko, Ichiro
AU - Hayashi, Atsushi
AU - Ueda-Consolvo, Tomoko
AU - Yanagi, Yasuo
N1 - Publisher Copyright:
© 2024 Lippincott Williams and Wilkins. All rights reserved.
PY - 2024/4/1
Y1 - 2024/4/1
N2 - Purpose:To investigate the incidence of intraocular inflammation (IOI) and its risk factors following intravitreal injections of brolucizumab for neovascular age-related macular degeneration in Japan.Methods:A total of 1,351 Japanese consecutive patients with neovascular age-related macular degeneration who were treated with brolucizumab from May 2020 to May 2022 at 14 institutions were examined. The variables analyzed were the number of brolucizumab injections, time to onset of IOI, and risk factors.Results:Intraocular inflammation developed in 152 eyes (11.3%). Retinal vasculitis and/or retinal occlusion occurred in 53 eyes (3.9%). Ninety-four patients received bilaterally, bilateral IOI occurred in five patients (5.3%). Sixteen eyes (1.2%) had irreversible visual acuity loss and nine eyes (0.67%) had visual loss of three lines or more due to retinal vasculitis and/or retinal occlusion. The cumulative IOI incidence was 4.5%, 10.3%, and 12.2% at 30, 180, and 365 days (1-year), respectively. History of IOI (including retinal vasculitis) and/or retinal occlusion (odds ratio [OR], 5.41; P = 0.0075) and female sex (OR, 1.99; P = 0.0004) were significantly associated with IOI onset.Conclusion:The 1-year cumulative incidence of IOI in Japanese neovascular age-related macular degeneration patients treated with brolucizumab was 12.2%. History of IOI (including retinal vasculitis) and/or retinal occlusion and female sex were significant risk factors.
AB - Purpose:To investigate the incidence of intraocular inflammation (IOI) and its risk factors following intravitreal injections of brolucizumab for neovascular age-related macular degeneration in Japan.Methods:A total of 1,351 Japanese consecutive patients with neovascular age-related macular degeneration who were treated with brolucizumab from May 2020 to May 2022 at 14 institutions were examined. The variables analyzed were the number of brolucizumab injections, time to onset of IOI, and risk factors.Results:Intraocular inflammation developed in 152 eyes (11.3%). Retinal vasculitis and/or retinal occlusion occurred in 53 eyes (3.9%). Ninety-four patients received bilaterally, bilateral IOI occurred in five patients (5.3%). Sixteen eyes (1.2%) had irreversible visual acuity loss and nine eyes (0.67%) had visual loss of three lines or more due to retinal vasculitis and/or retinal occlusion. The cumulative IOI incidence was 4.5%, 10.3%, and 12.2% at 30, 180, and 365 days (1-year), respectively. History of IOI (including retinal vasculitis) and/or retinal occlusion (odds ratio [OR], 5.41; P = 0.0075) and female sex (OR, 1.99; P = 0.0004) were significantly associated with IOI onset.Conclusion:The 1-year cumulative incidence of IOI in Japanese neovascular age-related macular degeneration patients treated with brolucizumab was 12.2%. History of IOI (including retinal vasculitis) and/or retinal occlusion and female sex were significant risk factors.
KW - age-related macular degeneration
KW - brolucizumab
KW - intraocular inflammation
KW - vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=85189375420&partnerID=8YFLogxK
U2 - 10.1097/IAE.0000000000004009
DO - 10.1097/IAE.0000000000004009
M3 - 学術論文
C2 - 38016089
AN - SCOPUS:85189375420
SN - 0275-004X
VL - 44
SP - 714
EP - 722
JO - Retina
JF - Retina
IS - 4
ER -